Antitumour activity of MDV3100 in castration-resistant prostate cancer: a phase 1–2 studyHoward I. Scher, Charles L. Sawyers, Celestia S. Higano et al.|The Lancet|2010Cited by 1.1k
Transcriptional profiling of matched patient biopsies clarifies molecular determinants of enzalutamide-induced lineage plasticityThomas C. Westbrook, Joshi J. Alumkal|Nature Communications|2022Cited by 59
LSD1 promotes prostate cancer reprogramming by repressing TP53 signaling independently of its demethylase functionAnbarasu Kumaraswamy, Joshi J. Alumkal|JCI Insight|2023Cited by 40
Maintenance of MYC expression promotes de novo resistance to BET bromodomain inhibition in castration-resistant prostate cancerDaniel J. Coleman, Joshi J. Alumkal|Scientific Reports|2019Cited by 36